Publications
Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis
Citation
Christopher Ma, Rish K Pai, David F Schaeffer, Jonathan Krell, Leonardo Guizzetti, Stefanie C McFarlane, John K MacDonald, Won-Tak Choi, Roger M Feakins, Richard Kirsch, Gregory Y Lauwers, Reetesh K Pai, Christophe Rosty, Amitabh Srivastava, Joanna C Walsh, Brian G Feagan, Vipul Jairath. Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis. J Immunother Cancer. 2022 Mar;10(3):e004560. DOI: 10.1136/jitc-2022-004560. PMID: 35296560 PMCID: PMC8928359 DOI: 10.1136/jitc-2022-004560.
Abstract
Immune checkpoint inhibitor-associated colitis (ICIC) affects approximately 15% of cancer patients treated with immunotherapy. Although histological evaluation is potentially valuable for both the diagnosis of ICIC and evaluation of disease activity, use in clinical practice is heterogeneous. We aimed to develop expert recommendations to standardize histological assessment of disease activity in patients with ICIC.